These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20811335)

  • 21. Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
    Sankarasubbaiyan S; Abraham G; Soundararajan P; Chandrasekaran V; Padma G
    Hemodial Int; 2005 Jan; 9(1):63-7. PubMed ID: 16191055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.
    Young EW; Albert JM; Satayathum S; Goodkin DA; Pisoni RL; Akiba T; Akizawa T; Kurokawa K; Bommer J; Piera L; Port FK
    Kidney Int; 2005 Mar; 67(3):1179-87. PubMed ID: 15698460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
    Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
    Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H; Fukagawa M;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
    Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
    Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Yamamoto S; Karaboyas A; Komaba H; Taniguchi M; Nomura T; Bieber BA; De Sequera P; Christensson A; Pisoni RL; Robinson BM; Fukagawa M
    BMC Nephrol; 2018 Oct; 19(1):253. PubMed ID: 30290781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
    Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of renal bone disease treatment in dialysis patients.
    Johnson CA; McCarthy J; Bailie GR; Deane J; Smith S
    Am J Kidney Dis; 2002 Jun; 39(6):1270-7. PubMed ID: 12046041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
    del Pozo-Fernández C; López-Menchero-Martínez R; Álvarez-Avellán L; Albero-Molina MD; Sánchez-Rodríguez L
    Nefrologia; 2013; 33(5):675-84. PubMed ID: 24089159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Renal osteodystrophy and growth in children undergoing CAPD].
    Ito T; Horiike S; Iitaka K
    Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):779-90. PubMed ID: 1770638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
    Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
    Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story.
    Kalantar-Zadeh K; Kovesdy CP
    Am J Kidney Dis; 2009 Feb; 53(2):183-8. PubMed ID: 19166796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.